摘要
目的分析血液透析患者不宁腿综合征采用加巴喷丁治疗的临床疗效。方法选取该院2018年6月-2019年5月收治的80例血液透析伴不宁腿综合征患者为研究对象,随机分为两组,对照组行常规对症治疗,观察组在血液灌流基础上联合加巴喷丁治疗,对比两组治疗前后RLS严重程度评分、PSQI(匹兹堡睡眠质量指数)评分、生活质量评分、不良反应发生情况。结果观察组治疗后IRLS评分为(13.22±0.18)分,低于对照组的(18.02±1.08)分(t=27.727,P<0.05);观察组治疗后PSQI为(6.02±0.15)分,低于对照组的(9.69±0.58)分(t=38.744,P<0.05);观察组治疗后生活质量评分为(95.85±2.22)分,高于对照组的(75.12±3.18)分(t=33.806,P<0.05)。结论血液透析伴不宁腿综合征患者在血液灌流基础上采用加巴喷丁治疗的临床疗效显著,利于改善患者睡眠状况,提高生活质量,且不良反应少,可推广。
Objective To analyze the clinical efficacy of restless leg syndrome treated with gabapentin in hemodialysis patients. Methods A total of 80 patients with hemodialysis and restless legs syndrome who were treated in the hospital from June 2018 to May 2019 were selected as the research objects. They were randomly divided into two groups. The control group received conventional symptomatic treatment. The observation group was based on hemoperfusion combined with gabapentin treatment, the RLS severity score, PSQI(Pittsburgh Sleep Quality Index) score, quality of life score, and adverse reactions were compared before and after treatment. Results The IRLS score of the observation group after treatment was(13.22±0.18) points, which was lower than that of the control group(18.02 ±1.08) points(t=27.727, P<0.05). The PSQI of the observation group after treatment was(6.02±0.15) points, lower than the control group of(9.69±0.58) points(t=38.744, P<0.05);the quality of life score in the observation group after treatment was(95.85±2.22) points, which was higher than the(75.12±3.18) points in the control group(t=33.806, P<0.05). Conclusion The clinical effect of gabapentin on hemodialysis patients with restless legs syndrome on the basis of hemoperfusion is significant, which is conducive to improving patients’ sleep status and quality of life, and has fewer adverse reactions,which can be promoted.
作者
王云霞
WANG Yun-xia(Department of Nephrology and Rheumatology,People's Hospital of Jinhu County,Jinhu,Jiangsu Province,211600 China)
出处
《系统医学》
2020年第4期30-32,共3页
Systems Medicine
